- Home
- CBRE vs EW Comparison
CBRE vs EW Comparison
Compare CBRE & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- EW
- Stock Information
- Founded
- CBRE 1906
- EW 1958
- Country
- CBRE United States
- EW United States
- Employees
- CBRE N/A
- EW N/A
- Industry
- CBRE Real Estate
- EW Industrial Specialties
- Sector
- CBRE Finance
- EW Health Care
- Exchange
- CBRE Nasdaq
- EW Nasdaq
- Market Cap
- CBRE 46.5B
- EW 45.5B
- IPO Year
- CBRE 2004
- EW 2000
- Fundamental
- Price
- CBRE $151.71
- EW $75.73
- Analyst Decision
- CBRE Buy
- EW Buy
- Analyst Count
- CBRE 9
- EW 18
- Target Price
- CBRE $166.33
- EW $86.29
- AVG Volume (30 Days)
- CBRE 1.4M
- EW 4.9M
- Earning Date
- CBRE 10-23-2025
- EW 10-23-2025
- Dividend Yield
- CBRE N/A
- EW N/A
- EPS Growth
- CBRE 19.77
- EW 188.09
- EPS
- CBRE 3.57
- EW 7.02
- Revenue
- CBRE $38,104,000,000.00
- EW $5,685,100,000.00
- Revenue This Year
- CBRE $14.31
- EW $13.23
- Revenue Next Year
- CBRE $10.11
- EW $9.76
- P/E Ratio
- CBRE $42.47
- EW $10.73
- Revenue Growth
- CBRE 14.96
- EW 9.14
- 52 Week Low
- CBRE $108.45
- EW $64.51
- 52 Week High
- CBRE $167.56
- EW $83.00
- Technical
- Relative Strength Index (RSI)
- CBRE 34.46
- EW 39.74
- Support Level
- CBRE $154.14
- EW $76.48
- Resistance Level
- CBRE $157.32
- EW $78.04
- Average True Range (ATR)
- CBRE 2.84
- EW 1.77
- MACD
- CBRE -1.34
- EW 0.13
- Stochastic Oscillator
- CBRE 0.00
- EW 37.30
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.